CSIMarket
 
Harvard Apparatus Regenerative Technology Inc   (BSTG)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 15
 Employees 12
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Harvard Apparatus Regenerative Technology Inc
Harvard Apparatus Regenerative Technology Inc (HART) is a biotechnology company focused on developing regenerative medicine products for tissue engineering and cell therapy applications. The company's goal is to advance the field of regenerative medicine by creating innovative solutions that can repair or replace damaged tissues and organs.

HART has expertise in bioengineering, stem cell biology, and tissue engineering, which enables them to develop and commercialize novel products. They have developed a range of advanced technologies, including 3D bioprinting, tissue scaffolds, and cell culture systems, that facilitate the growth and differentiation of cells for therapeutic purposes.

The company's products are designed to address various medical conditions, such as chronic wounds, organ failure, and degenerative diseases. They aim to improve patient outcomes and quality of life by providing innovative treatments that can potentially restore normal tissue function.

HART collaborates with academic institutions, research organizations, and industry partners to advance their research and development efforts. They also work closely with regulatory agencies to ensure compliance with safety and efficacy standards.

In summary, Harvard Apparatus Regenerative Technology Inc is a biotechnology company that specializes in developing regenerative medicine products to repair and replace damaged tissues and organs. They aim to revolutionize the field of regenerative medicine by offering innovative solutions to treat various medical conditions.


   Company Address: 84 October Hill Road Holliston 1746 MA
   Company Phone Number: 233-7300   Stock Exchange / Ticker: BSTG


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CTCX   -24.68%    
TSOI        50% 
VYCO        52.43% 
ORGO   -4.51%    
TARS        10.05% 
VCEL        4.48% 
• View Complete Report
   



Harvard Apparatus Regenerative Technology Inc

Harvard Apparatus Regenerative Technology Inc Reports Decreased Net Deficit in First Quarter



In the world of finance, every company's financial results tell a story. Today, we analyze the fiscal first-quarter results of BSTG and Harvard Apparatus Regenerative Technology Inc (HARV). While BSTG saw a positive swing in revenue, HARV reported a decreased net deficit in comparison to the same quarter last year. These contrasting figures pique our curiosity as we explore the implications for both companies moving forward.
BSTG's Revenue Surge:
During the fiscal first quarter of 2024, BSTG generated $0.057 million in revenue. Although seemingly modest, this figure signifies a positive development for the company. It indicates growth and a potential uptick in demand for the products or services offered by BSTG. This increase in revenue might signify successful product launches, improved market positioning, or strong customer retention. It serves as a stepping stone for future growth and profitability. Going forward, BSTG should leverage this momentum to further expand its customer base and solidify its market presence.

Harvard Apparatus Regenerative Technology Inc

Demonstrating Resilience and Potential Growth in Challenging Times



Despite facing a net shortfall in revenue and increased losses, Harvard Apparatus Regenerative Technology Inc, a prominent player in the Medical Equipment & Supplies industry, has demonstrated its resilience and potential for growth. The financial results of the company for the fiscal year ending on December 31, 2023, shed light on their commitment to innovation and long-term success.
Revenue Growth and Business Expansion:
In the face of challenging circumstances, Harvard Apparatus Regenerative Technology Inc managed to generate revenue of $0.063 million for the financial period ending December 31, 2023. This signifies a positive trend for the company, showcasing its ability to adapt to market evolutions and continue generating substantial revenue. Furthermore, the company's announcement of revenue of $0.10 million in the fiscal year 2023 is indicative of potential growth and future success.

Harvard Apparatus Regenerative Technology Inc

Harvard Apparatus Regenerative Technology Inc published Revenue of $0.04 million, in the July to September 30 2023

Harvard Apparatus Regenerative Technology Inc, a renowned Medical Equipment & Supplies company, recently announced its financial results for the interval ending September 30, 2023. The company reported revenue of $0.04 million during this period. Unfortunately, the company also recognized a net shortfall of $-1.615 million, which is higher compared to the previous year's figure of $-1.056 million.
These financial results shed light on the challenges faced by Harvard Apparatus Regenerative Technology Inc. While the company experienced a minimal increase in revenue, its net shortfall increased significantly. This suggests that the company's expenses may have exceeded its revenue, resulting in a negative net income.

Biostage Inc

Biostage Inc Faces Significant Operating Deficit of $-2.651 Million in Q2 2023; Raises Concerns for Company's Financial Management

Biostage Inc is a medical equipment and supplies company that is currently facing some challenges within the industry. As industry veterans continue to analyze the second quarter of 2023 numbers, they have noticed a significant operating deficit of $-2.651 million from Biostage Inc. This is a concerning figure, especially considering the lack of specified top-line revenue.
In comparison to the second quarter of 2022, the operating deficit has actually worsened, increasing from $-1.375 million. This highlights a potential issue within the company's financial management and operational efficiency. It is important for Biostage Inc to address this deficit and find ways to improve their financial performance.







Harvard Apparatus Regenerative Technology Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com